Proscan

• Metastatic prostatic carcinoma (Stage D2) - in combination with LHRH agonist
• Adjunctive therapy to orchiectomy
• Bulky locally advanced Stage B2 and Stage C prostatic carcinoma - prior to and during external beam radiotherapy

In animal studies, flutamide demonstrates potent antiandrogenic effects. It exerts its antiandrogenic action by inhibiting androgen uptake and/or by inhibiting nuclear binding of androgen in target tissues or both. Prostatic carcinoma is known to be androgen-sensitive and responds to treatment that counteracts the effect of androgen and/or removes the source of androgen.

Adult Dose:

• In combination with orchiectomy or LHRH agonist: 250 mg tablet three times a day at eight-hour intervals.
• Stage B2 and C prostatic carcinoma: 250 mg three times a day at eight-hour intervals. Start 8 weeks prior to radiation therapy and continue through the course.

* Use as directed by the registered physician

Common Side Effects:

• Breast enlargement in males - 9%
• Nausea/Vomiting - 11%
• Diarrhea - 12%
• Anorexia - 4%
• CNS reactions (drowsiness/confusion/depression/anxiety) - 1%
• Anemia - 6%
• Leukopenia - 3%
• Thrombocytopenia - 1%
• Hypertension - 1%

Serious Side Effects: Hepatic injury (hepatitis, jaundice, hepatic necrosis) - <1%.

Use in Pregnancy: Unsafe during pregnancy. There is definite evidence of risk to the developing baby.

Precautions:

• Periodic liver function tests and sperm count determinations must be performed on long-term treatment.
• Inform doctor if you develop signs of liver injury (pruritus, dark urine, persistent anorexia, jaundice, right upper quadrant tenderness or unexplained flu-like symptoms).
• Use with caution in cardiac disease (may cause fluid retention).
• Avoid during pregnancy and lactation.

Overdose: Limited information available on overdose. Employ usual supportive measures.

Storage: Keep below 30°C, away from light and moisture. Keep out of reach of children.